159 related articles for article (PubMed ID: 33343821)
1. A Retrospective Cost Analysis of Patients Who Switched from OnabotulinumtoxinA to IncobotulinumtoxinA in a Private Neurology Practice.
Karschney VK; Greeley DR
Am Health Drug Benefits; 2020; 13(5):205-210. PubMed ID: 33343821
[TBL] [Abstract][Full Text] [Related]
2. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
Kazerooni R; Watanabe JH
J Manag Care Spec Pharm; 2021 Apr; 27(4):478-487. PubMed ID: 33511895
[No Abstract] [Full Text] [Related]
3. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
Grosset DG; Tyrrell EG; Grosset KA
J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
[TBL] [Abstract][Full Text] [Related]
4. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
[TBL] [Abstract][Full Text] [Related]
5. Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.
Thomas AJ; Larson MO; Braden S; Cannon RB; Ward PD
JAMA Facial Plast Surg; 2018 Mar; 20(2):141-147. PubMed ID: 28973094
[TBL] [Abstract][Full Text] [Related]
6. Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II.
Kent R; Robertson A; Quiñones Aguilar S; Tzoulis C; Maltman J
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357959
[TBL] [Abstract][Full Text] [Related]
7. Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits.
Kazerooni R; Howard I; Li X; Verduzco-Gutierrez M
Arch Phys Med Rehabil; 2022 Jun; 103(6):1205-1209. PubMed ID: 34852255
[TBL] [Abstract][Full Text] [Related]
8. Real-World Six-Year National Cost-Minimization Analysis of IncobotulinumtoxinA and OnabotulinumtoxinA in the VA/DoD Healthcare Systems.
Kazerooni R; Howard IM; Keener AM; Bounthavong M
Clinicoecon Outcomes Res; 2021; 13():603-609. PubMed ID: 34234482
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment.
Trosch RM; Shillington AC; English ML; Marchese D
J Manag Care Spec Pharm; 2015 Oct; 21(10):854-60. PubMed ID: 26402386
[TBL] [Abstract][Full Text] [Related]
10. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
[TBL] [Abstract][Full Text] [Related]
11. A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.
Wilson AJ; Chang B; Taglienti AJ; Chin BC; Chang CS; Folsom N; Percec I
Plast Reconstr Surg; 2016 May; 137(5):1424-1433. PubMed ID: 27119918
[TBL] [Abstract][Full Text] [Related]
12. Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia.
Bladen JC; Favor M; Litwin A; Malhotra R
Clin Exp Ophthalmol; 2020 Dec; 48(9):1146-1151. PubMed ID: 32710447
[TBL] [Abstract][Full Text] [Related]
13. AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.
Abogunrin S; Brand S; Desai K; Dinet J; Gabriel S; Harrower T
Clinicoecon Outcomes Res; 2015; 7():441-9. PubMed ID: 26392782
[TBL] [Abstract][Full Text] [Related]
14. Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study.
Rappl T; Parvizi D; Friedl H; Wiedner M; May S; Kranzelbinder B; Wurzer P; Hellbom B
Clin Cosmet Investig Dermatol; 2013; 6():211-9. PubMed ID: 24098087
[TBL] [Abstract][Full Text] [Related]
15. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
Shome D; Kapoor R; Khare S
J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of type A botulinum toxins for aesthetic indications and their relative economic impact.
Jandhyala R
J Plast Reconstr Aesthet Surg; 2012 Jun; 65(6):720-31. PubMed ID: 22225675
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice.
Prager W; Huber-Vorländer J; Taufig AZ; Imhof M; Kühne U; Weissberg R; Kuhr LP; Rippmann V; Philipp-Dormston WG; Proebstle TM; Roth C; Kerscher M; Ulmann C; Pavicic T
Clin Cosmet Investig Dermatol; 2012; 5():53-8. PubMed ID: 22791996
[TBL] [Abstract][Full Text] [Related]
18. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
Chundury RV; Couch SM; Holds JB
Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
[TBL] [Abstract][Full Text] [Related]
19. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
Jimenez-Shahed J
Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
[TBL] [Abstract][Full Text] [Related]
20. IncobotulinumtoxinA for Post-stroke Upper Limb Spasticity in Neutralizing Antibody-positive Patients after Botulinum Toxin Therapy: A Report of Two Cases.
Masakado Y; Dekundy A; Tateishi S; Kaji R
Prog Rehabil Med; 2022; 7():20220012. PubMed ID: 35342835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
